(via NewsDirect)
Ananda Developments (AQSE:ANA) co-founder and CEO
Sturgess says that cannabinoid-based medicine will ultimately become "completely ubiquitous" and highlights the various fronts that Ananda is currently pushing forward on, including two upcoming phase II randomised controlled clinical trials.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source